[1]许建中,张泽华,万东勇,等.药敏试验指导下脊柱结核个体化药物治疗[J].第三军医大学学报,2009,31(20):1926-1928.
 XU Jian-zhong,ZHANG Ze-hua,WAN Dong-yong,et al.Drug susceptibility-guided individual anti-tuberculous chemotherapy for spinal tuberculosis: report of 46 cases[J].J Third Mil Med Univ,2009,31(20):1926-1928.
点击复制

药敏试验指导下脊柱结核个体化药物治疗(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
31卷
期数:
2009年第20期
页码:
1926-1928
栏目:
专题报道
出版日期:
2009-10-30

文章信息/Info

Title:
Drug susceptibility-guided individual anti-tuberculous chemotherapy for spinal tuberculosis: report of 46 cases
作者:
许建中张泽华万东勇周强廖传玉赵小莉何清义代飞
第三军医大学西南医院骨科,全军矫形外科中心;重庆市胸科医院检验科
Author(s):
XU Jian-zhong ZHANG Ze-hua WAN Dong-yong ZHOU Qiang LIAO Chuan-yu ZHAO Xiao-li HE Qing-yi DAI Fei
Department of Orthopaedics, Southwest Hospital, Third Military Medical University, Chongqing 400038; Department of Clinical Laboratory, Thoracic Hospital of Chongqing City, Chongqing 400036, China
关键词:
脊柱结核耐药药敏试验个体化抗结核药物治疗
Keywords:
spinal tuberculosis drug resistance drug susceptibility testing individual antit-uberculous chemotherapy
分类号:
R453;R529.2;R965
文献标志码:
A
摘要:
目的   实施结核分枝杆菌药敏试验指导下脊柱结核个体化化疗,探讨其有效性及安全性。   方法   46例脊柱结核患者接受手术治疗,术中收集脓液、干酪样组织,常规处理后接种液体培养基,使用BACT/ALERT 3D系统进行结核分枝杆菌快速培养,培养阳性者接种至改良罗氏培养基,按绝对浓度法进行11种药物药敏试验。根据药敏试验结果制定4-5药联合抗结核药物治疗方案。定期(1、3、6、9、12个月,以后每6个月1次)随访,观察血沉、平片、CT三维重建,评估结核活动、骨块融合和畸形矫正情况。   结果   培养阳性率41.3%(19/46),全程平均耗时42 d(30~58 d)。耐药率21.7%,其中异烟肼耐药10.8%,利福平和乙胺丁醇耐药2.1%,链霉素耐药6.52%,力克肺疾耐药4.34%,左氧氟沙星耐药17.39%。除4例明显胃肠道反应、1例药物型肝炎患者完成12个月疗程,其余18个月。随访18~44个月,平均25个月,切口均2周内愈合。椎间植骨均获Ⅰ级骨性融合,融合时间9~12个月。   结论   根据药敏试验结果组成脊柱结核12~18个月个体化联合化疗方案具有较好的有效性和安全性。
Abstract:
Objective   To investigate the efficacy and safety of individual anti-tuberculous chemotherapy guided by drug susceptibility testing for spinal tuberculosis by analyzing the post-operative follow-up outcomes.    Methods   In this series, the diagnoses of spinal tuberculosis were established based on clinical, radiological and histological arguments in 46 patients who were admitted from August 2005 to March 2009. Their specimens (pus or caseous tissue) were collected during surgery. After processed in a routine mycobacteriology laboratory procedure, the specimens were inoculated into vials of the BACT/ALERT 3D system. The drug susceptibility testing was performed using absolute concentration method, which included 11 first and second line drugs. Four or five anti-tuberculous drug regimen was chosen according to the results of drug susceptibility testing. All the patients were followed up regularly a month later, and then every 3 months for the following 11 months, and subsequently at intervals of half a year. The clinical status, erythrocyte sedimentation rate (ESR), roentgenogram and 3D-CT were concerned to estimate the progress of tuberculosis. Radiographs were analyzed before surgery, immediately after surgery, and at the final follow-up examination to assess the result of anterior fusion and maintenance of correction.    Results   Nineteen of the total 46 specimens were culture positive (41.3%). The average detection time to report drug susceptibility was 42 d (ranging from 30 to 58 d). The drug susceptibility testing showed a resistance level of 10.8% for isoniazid, 2.1% for rifampicin and ethambutol, 6.52% for streptomycin, 4.34% for dipasic and 17.396% for levofloxacin. Four patients with gastrointestinal reaction and 1 with anti-tuberculosis drug-induced hepatitis completed a 12 months’ therapy, and the others received a 18 month’ therapy. The mean follow-up period was 25 months (ranging from 18 to 44 months), and no obvious loss of deformity correction was observed. According to Bridwell criteria, grade Ⅰbony fusion was obtained in all patients in 9 to 12 months.    Conclusion   If guided by drug susceptibility testing, individual anti-tuberculous chemotherapy for 12 to 18 months is effective and safe for spinal tuberculosis.

参考文献/References:

许建中, 张泽华, 万东勇, 等. 药敏试验指导下脊柱结核个体化药物治疗[J]. 第三军医大学学报,2009,31(20):1926-1928.

相似文献/References:

[1]吴国明,钱桂生.晚期非小细胞肺癌EGFR-TKIs治疗的耐药机制研究——挑战中蕴含新的曙光[J].第三军医大学学报,2012,34(20):2031.
 Wu Guoming,Qian Guisheng.Drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in treatment of advanced non-small cell lung cancer—A new dawn in challenge[J].J Third Mil Med Univ,2012,34(20):2031.
[2]祝冰晶,王宇亮,罗虎,等.CA916798基因通过PI3K/AKT通路参与肺癌顺铂耐药[J].第三军医大学学报,2013,35(07):618.
 Zhu Bingjing,Wang Yuliang,Luo Hu,et al.CA916798 gene is involved in cisplatin resistance in human lung cancer through PI3K/AKT pathway[J].J Third Mil Med Univ,2013,35(20):618.
[3]周艳,姜军,张毅,等.雌激素受体β及其剪切变异体表达与雌激素受体阻滞剂治疗耐药的关系[J].第三军医大学学报,2007,29(20):1999.
 ZHOU Yan,JIANG Jun,ZHANG Yi,et al.Relationship of estrogen receptor-beta and its isoform expressions with tamoxifen resistance in human breast cancer[J].J Third Mil Med Univ,2007,29(20):1999.
[4]向征,张才全,汤为学.TSG101-siRNA对肝癌耐药细胞株QGY/CDDP的逆转作用[J].第三军医大学学报,2008,30(02):170.
 XIANG Zheng,ZHANG Cai-quan,TANG Wei-xue.Effect of tumor susceptibitity gene 101-siRNA eukaryotic expression vector and cisplatin on proliferation of QGY/CDDP[J].J Third Mil Med Univ,2008,30(20):170.
[5]林辉,刘洁,陈林,等.重庆市2003-2006年肺结核病耐药情况分析[J].第三军医大学学报,2008,30(12):1183.
 LIN Hui,LIU Jie,CHEN Lin,et al.Drug resistance of tuberculosis from 2003 to 2006 in Chongqing[J].J Third Mil Med Univ,2008,30(20):1183.
[6]陈幸华,张诚,张曦,等.人淋巴细胞白血病细胞黏附介导耐药模型构建初探[J].第三军医大学学报,2006,28(23):2336.
[7]权正学,蒋电明,欧云生.一期病灶清除植骨内固定治疗颈椎结核的疗效[J].第三军医大学学报,2006,28(13):1435.
[8]房殿亮,陈伟庆.p15基因干扰对肝癌耐药的影响[J].第三军医大学学报,2011,33(16):1695.
 Fang Dianliang,Chen Weiqing.Influence of siRNA-mediated p15 silencing on CDDP resistance in drug-resistant human hepatoma cell line HepG2/CDDP/2.0[J].J Third Mil Med Univ,2011,33(20):1695.
[9]张宏其,赵迪,陈凌强,等.经后路一期病灶清除植骨融合内固定矫形治疗伴后凸畸形的儿童颈胸段脊柱结核[J].第三军医大学学报,2009,31(20):1951.
 ZHANG Hong-qi,ZHAO Di,CHEN Ling-qiang,et al.One-stage posterior debridment, bone grafting and internal fixation for cervicothoracic tuberculosis accompanied by kyphosis in children[J].J Third Mil Med Univ,2009,31(20):1951.
[10]王洪波,叶尔江·达哈尔,金格勒,等.脊柱结核术后复发因素的作用强度对比分析[J].第三军医大学学报,2009,31(20):1955.
 WANG Hong-bo,YEERJIANG·Dahaer,JIN Ge-le,et al.Risk factors of postoperative recurrence of spinal tuberculosis: a comparative analysis on 486 cases[J].J Third Mil Med Univ,2009,31(20):1955.
[11]许建中.脊柱结核治疗中面临的几个问题[J].第三军医大学学报,2009,31(20):1923.
[12]程鹏,张泽华,李力韬,等.基因芯片法快速检测脊柱结核临床分离株SM、EMB、LVFX、AMK、CPM耐药[J].第三军医大学学报,2014,36(13):1345.
 Cheng Peng,Zhang Zehua,Li Litao,et al.Rapid detection of SM/EMB/LVFX/AMK/CPM resistance by DNA microarray for clinical isolates from spinal tuberculosis[J].J Third Mil Med Univ,2014,36(20):1345.

更新日期/Last Update: 2009-10-21